Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Contact us

07 3737 4500

PO Box 3787

South Brisbane QLD 4101

Dr Michael Huo

MBBS, FRANZCR

  • Radiation Oncologist

Biography

Dr Michael Huo is committed to ensuring his patients receive exceptional, evidence-based cancer care.

Dr Michael Huo is a radiation oncologist at Icon Cancer Centre Greenslopes and Icon Cancer Centre Redland. Raised in Brisbane, he completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at the University of Queensland (UQ). He completed radiation oncology training in Cairns, Toowoomba and Brisbane, followed by a 12-month clinical fellowship at the world-renowned Princess Margaret Hospital in Toronto, Canada where he subspecialised in Gamma Knife radiosurgery and palliative radiation therapy. In 2019 he became the inaugural Gamma Knife Fellow at the Princess Alexandra Hospital before his appointment as a Staff Specialist in 2020.

He has a public appointment at the PA Hospital and Gamma Knife Centre of Queensland, where he is a Director of Training for Radiation Oncology. He is also an examiner and senior lecturer for the University of Queensland School of Medicine. He is a member of the TROG Genitourinary Cancer Working Party, and the Principal Investigator for research studies involving Gamma Knife radiosurgery, kidney SBRT and cardiac radioablation. He has contributed numerous peer-reviewed publications and textbook chapters, in addition to conference presentations at local, national and international levels.

He subspecialises in urological cancers including prostate, kidney and bladder cancers, as well as Stereotactic Radiosurgery for brain metastases, benign tumours (such as pituitary adenomas and meningiomas), and other intracranial conditions.

Dr Huo is fluent in English and Mandarin, ensuring patients and their families feel comfortable communicating in their preferred language.

Publications

  • Importance of Cobalt-60 Dose Rate and Biologically Effective Dose on Local Control for Intracranial Meningiomas Treated With Stereotactic Radiosurgery. M. Huo, M. Rose, M. van Prooijen, M. Cusimano, N. Laperriere, R. Heaton, F. Gentili, D. Payne, D. Shultz, P. Kongkham, S. Kalia, M. Schwartz, M. Bernstein, J. Spears, G. Zadeh, M. Hodaie & D. Tsang. Neurosurgery, 2022; 90: 140-147.

  • Outcomes Following Hypofractionated Stereotactic Radiotherapy to the Cavity After Surgery for Melanoma Brain Metastases. J. Gallo, S. Garimall, M. Shanker, J. Castelli, T. Watkins, S. Olson, M. Huo, M.C. Foote & M. Pinkham. Clinical Oncology (R Coll Radiol), 2021.

  • Renal Cell Carcinoma Metastasis to Meckel’s Cave Treated With Repeat Stereotactic Radiosurgery: A Case Report and Review of the Literature. J. Panizza, M. Pinkham, M. Foote, M. Shanker, K. Horwood & M. Huo. Cureus, 2021; 13.

  • Efficacy of stereotactic radiosurgery for radiation-induced meningiomas. M. Huo, N. Laperriere, M. van Prooijen, D. Shultz, C. Coolens, M. Hodaie, M. Cusimano, F. Gentili, G. Zadeh, D. Payne, M. Schwartz & D. Tsang. Journal of Neuro-Oncology, 2020. 148(5).